MedTrace Logo

Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)

NCT01635803 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 296

Last updated 2015-07-01

No results posted yet for this study

Summary

The primary objective is to demonstrate the non-inferiority of bevacizumab in the treatment of patients with macular edema secondary to a retinal vein occlusion (branch or central) as determined by the change in best-corrected visual acuity in the study eye from baseline to month 6.

Conditions

  • Retinal Vein Occlusion

Interventions

DRUG

Bevacizumab

1.25 mg bevacizumab administered by monthly interval for six months (6 injections).

DRUG

Ranibizumab

0.5mg ranibizumab administered by monthly interval for six months (6 injections).

Sponsors & Collaborators

  • Leiden University Medical Center

    collaborator OTHER

  • Free University Medical Center

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Reinier O Schlingemann, MD, PhD · Academic Medical Center, Dept. Ophthalmology, Room A2-122, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01635803 on ClinicalTrials.gov